Veracyte, Inc.
VCYT· Nasdaq
VCYTVeracyte, Inc.
Source filing unavailable
| Metric | Q2 2013 | Q2 2012 |
|---|---|---|
| Revenue | $5.07M | $2.48M |
| Net Income | -$6.49M | -$4.63M |
| EPS Diluted | -$7.53 | -$7.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Veracyte, Inc. · CIK 1384101 · Engraved from SEC EDGAR
